Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

eWall for Active Long Living

eWALL

Independent living of senior citizens is one of the main challenges linked to the ageing population, due to the impact on: (a) the life of the elderly people, (b) the national health systems, (c) the insurance companies, (d) the relatives and (e) the care-givers. Senior citizens may suffer from a number of diseases, including the decline in...

Funding Programme
Start Date
End Date
Total Funding
€ 8 838 005

Exploring inflammasome activation and targeted inhibition

NalpACT

Inflammasomes are cytosolic multi-protein complexes that form in response to a wide range of pathogens, tissue damage, and other harmful stimuli. Members of the family of NOD-like receptors (NLRs) sense these pathogen and danger associated molecular patterns, triggering innate immune responses. NLRP3 is a well-studied NLR whose activation by a...

Funding Programme
Start Date
End Date
Total Funding
€ 2 155 047
European Countries Involved

Exposing the glial metabolism - common link to brain damage

LipidGlia

European population is rapidly aging. While it was commonly believed that brain aging leads to neuronal loss, recent studies found that instead the volume of white matter (WM) decreases and WM lesions develop with age. WM degeneration is also a hallmark of multiple neurological disorders including Alzheimers disease or multiple sclerosis...

Funding Programme
Start Date
End Date
Total Funding
€ 173 847
European Countries Involved

FLuorescent nanO-agents for super-Resolution Imaging and seNsing

FLORIN

Since Alzheimer disease (AD) affects up to 50% of individuals above 85, we will witness the three-fold increase in the number of patients by 2050 if no efficient therapy will be found. The FLORIN offers non-invasive real-time monitoring of key mechanisms involved in the AD pathogenesis by avant-garde bioimaging at temporal resolution less than 1...

Funding Programme
Start Date
End Date
Total Funding
€ 791 200
European Countries Involved

Functional analysis of TSPAN14 as a genetic risk factor for Alzheimer’s disease

TSPAN14-AD

Alzheimer’s disease (AD) is the most prevalent deadly neurodegenerative disorder for which no effective treatment exists as of today. Therefore, there is an urgent need to better understand the molecular mechanisms behind AD in order to develop more effective treatments against this complex disease. Recent genetic findings have highlighted several...

Funding Programme
Start Date
End Date
Total Funding
€ 173 847
European Countries Involved

Generalised EMF Research using Novel Methods – an integrated approach: from research to risk assessment and support to risk management

GERONIMO

The EU population is increasingly exposed to new physical and chemical agents in the environment, some of which may be detrimental to public health. Of these, electromagnetic fields (EMF) are one of the most ubiquitous, with new EMF technologies and novel applications being actively developed and commercialised. To address pertinent questions on...

Funding Programme
Start Date
End Date
Total Funding
€ 7 853 407

Generation of Improved Cellular and Animal Models for Identification of Disease Phenotype and New Therapeutic Targets of Alzheimer’s Disease

MADGIC

The mechanisms of Alzheimer’s disease (AD) have remained poorly understood while com- mon animal models have not helped in finding efficient therapies for the disease. This pro- ject aims to generate new human cellular models allowing for the purification of specific neural cell types involved in AD. We generate patient neural cells through...

Funding Programme
Start Date
End Date
Total Funding
€ 1 901 835
European Countries Involved

Grammar and memory: Evidence from agrammatic aphasia and probable Alzheimer's disease in German, Italian and Greek

MemoGram

In Europe, there is an increasing number of people with neurological problems, such as probable Alzheimer’s disease (pAD) or aphasia, which often result in severe language and memory impairments. It has been argued that memory deficits contribute to the language problems brain-damaged populations face and, further, can predict these populations’...

Funding Programme
Start Date
End Date
Total Funding
€ 216 953
European Countries Involved

GSK-3 in neuronal plasticity and neurodegeneration: basic mechanisms and pre-clinical assessment

NEURO.GSK3

Neuronal circuits in mammalian brain act predominantly via excitatory synapses on dendritic spines. Formation of new spines in adult brain constitutes the structural basis of neuronal plasticity. The underlying molecular mechanisms remain largely unknown but depend essentially on kinase-dependent signalling pathways. Final formation of synapses on...

Funding Programme
Start Date
End Date
Total Funding
€ 5 082 027
European Countries Involved

High Resolution Segmentation of Brain MR Images at 7 Teslas

HIRESBRAIN7T

The advent of magnetic resonance imaging (MRI) technology has brought us closer to understanding brain function in health and disease. With 7 Teslas high field MRI machines, pioneers of imaging physics have made possible in-vivo examination of the human brain at sub-millimetre scale. New imaging contrasts additionally offer rich information...

Funding Programme
Start Date
End Date
Total Funding
€ 100 000
European Countries Involved

High-Throughput, High-Content Screening of human neuroectodermal organoids for innovative drug discovery in neurodegenerative diseases

3DMiniBrain

The goal of the 3D MiniBrain project is to establish and standardize the use of miniaturized human brain-like structures as a relevant three-dimensional (3D) testbed to decipher the roles of the main genetic risk factors for Alzheimer's disease and Parkinson's disease, according to original hypotheses obtained from our genetic studies. Minibrains...

Funding Programme
Start Date
End Date
Total Funding
€ 1 071 595
European Countries Involved

Holographic super-resolution micro-endoscopy for in-vivo applications

LIFEGATE

Complexity of living matter currently poses the most significant barrier to modern in-vivo microscopy. Fuelled by various branches of life sciences, the race is now to increase the penetration depth of super-resolution imaging inside living organisms. Additionally, no high-resolution in-vivo imaging technique has ever been introduced into medical...

Funding Programme
Start Date
End Date
Total Funding
€ 1 997 973
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).